The promise of anti-ErbB3 monoclonals as new cancer therapeutics

In the last 3-5 years strong evidence has been gathered demonstrating ErbB3 as a key node for the progression of several cancer types. From the mechanistic standpoint the intracellular region of this receptor is rich of tyrosine residues that, upon phosphorylation, become high affinity binding sites...

Descripción completa

Detalles Bibliográficos
Autores principales: Aurisicchio, Luigi, Marra, Emanuele, Roscilli, Giuseppe, Mancini, Rita, Ciliberto, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2012
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478453/
https://www.ncbi.nlm.nih.gov/pubmed/22889873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478453/
https://www.ncbi.nlm.nih.gov/pubmed/22889873

Ejemplares similares